MAY 11, 2017 12:00 PM PDT

Impact of Next-Generation Sequencing on Precision Medicine

Speaker
  • Vice President and Distinguished Scientist Illumina
    Biography
      Dr. Schroth is currently a Vice President and Distinguished Scientist at Illumina where he directs the Core Applications Group based in San Diego.

      He obtained his Ph.D. in biochemistry from the University of California at Davis and has been working in the field of next-generation sequencing (NGS) for more than a decade as part of Illumina (and Solexa).

      In his research Dr. Schroth uses NGS to study genomics, gene structure, expression and regulation and applies this to genomic projects in the fields of cancer, microbiology and infectious disease.

      Over the course of his career Dr. Schroth has published over 90 peer reviewed research papers and holds 17 U.S. patents.

    Abstract

    It was 10 years ago that Illumina first launched the Genome Analyzer II, the world’s first high-throughput sequencing platform.  That system could produce one billion bps of sequence information of data per run, which helped ignite a new revolution in genomics.   The past decade has seen further advances in data throughput, cost reductions, improved data quality and, most importantly, applications of next-generation sequencing.  In this talk we will discuss how NGS has specifically enabled entire new areas of research and testing in the field of precision medicine, including human genome and exome sequencing, human microbiome analysis, and elucidation of the molecular details of human cancer.  This talk will highlight the latest improvements in NGS and the interrelationships between science and technology in the field of personalized medicine.


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    MAY 11, 2017 12:00 PM PDT

    Impact of Next-Generation Sequencing on Precision Medicine


    Specialty

    Dna

    Genetics

    Cancer Research

    Biotechnology

    Bioinformatics

    Microbiology

    Cancer

    Gene Expression

    Cell Culture

    Molecular Diagnostics

    Personalized Medicine

    Genomics

    Disease

    Immunology

    Biomarkers

    Geography

    North America29%

    Europe29%

    Asia14%

    Africa14%

    Registration Source

    Website Visitors100%

    Job Title

    Student33%

    Educator/Faculty33%

    Clinical Laboratory Scientist17%

    Scientist17%

    Organization

    Academic Institution57%

    Biotech Company14%

    Research Institute14%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more